Vaccines, which can be complicated and expensive to manufacture, haven't always been the moneymakers they are for some drugmakers today. Last year, the global vaccines market topped $25.56 billion according to EvaluatePharma, with the world's 6 top-selling shots each cracking the blockbuster barrier.
It's a small group of drugmakers that are enjoying vaccines' top-line success. The top three vaccine players--Merck, Sanofi and GlaxoSmithKline, in that order--generated nearly two-thirds of that haul, EP says. Add Pfizer and Novartis to round out the top 5, and the group raked in more than 86% of all vaccine sales.
For now, these 5 are at the front of the pack. Take a look at the report to see how they're doing it and what lies ahead as they look to maintain their leads--or bow out, as the case may be.
Pfizer's Prevnar 13 currently dominates the list of the world's best-selling vaccines--and that won't be changing anytime soon, according to a new report from EvaluatePharma. In fact, it's expected to widen its lead, with sales growing more than 61% over the next 5+ years; by 2020, it will be generating nearly $4 billion more than runner up Pentacel from Sanofi, EP predicts.
As far as the rest of the list, however, EP anticipates a bit of shuffling. Merck's Gardasil, last year's No. 2 seller, will slide into third place to make room for Pentacel. And GlaxoSmithKline's Pediarix will inch up into fifth, knocking Merck's varicella jab Varivax out of the top 5.
Take a look at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013.
The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top. The "go big or go home" mentality has sent Novartis packing, with the Swiss company selling GSK most of its vaccines unit earlier this year as it made moves to exit the space. Pfizer, on the other hand, is scouting for ways to bulk up, earlier this month listing AstraZeneca's vaccine assets among the benefits of a potential merger.
For now, though, behind Pfizer's market-leading Prevnar 13, it's jabs from the leading triumvirate that bring in the bulk of vaccine sales. Merck, in particular, took four of the 10 top-selling spots, with Glaxo and Sanofi nabbing two apiece.
POPULAR COMMENT THREADS
It's taken 30 years, but GlaxoSmithKline's experimental malaria vaccine is finally ready for regulatory review. Looking to bring the world's first shot for the mosquito-borne disease to market, the pharma giant said Thursday that it has submitted its candidate for approval.
Though Merck's Gardasil tops the company's best-selling vaccines list and has already achieved blockbuster sales, the drug giant has a long way to go if it wants to boost U.S. immunization rates against human papillomavirus.
With Novartis and Pfizer racing for approval in a wide-open U.S. market, the Swiss pharma is taking the opportunity to expand its lead elsewhere, where its vaccine, Bexsero, has an expansive patient pool all to itself. And so far, it's going well, Novartis says.
Prevnar's lonely days are over. Pfizer is finally beefing up beyond its best-selling franchise--a long-stated objective of CEO Ian Read's--nabbing Baxter's marketed vaccines portfolio in a $635 million deal.
Aduro BioTech's GVAX, a previously failed cancer vaccine, is finding new life in a combination treatment that the Berkeley-based company is testing in patients with pancreatic cancer.
AstraZeneca's MedImmune has joined up with immunotherapy maker Advaxis to evaluate the Big Pharma's antibody MEDI4736 in conjunction with the Princeton, NJ-based biotech's lead cancer vaccine in patients with HPV-related cancers.
From Our Sister Sites
A global team of researchers believe they've developed a blood test that could prevent neural tube birth defects such as spina bifida.
The daring burglary of an Eli Lilly warehouse in 2010 was a record-setter by any number of measures. The parsing of the losses in insurance documents serves as a primer for the collateral damage that accrues from a large theft.